Back HBV Disease Progression Fibrosis/Cirrhosis

Fibrosis & Cirrhosis

Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation

In a head-to-head comparison, entecavir (Baraclude) demonstrated superior virological efficacy compared to adefovir (Hepsera) in hepatitis B patients with decompensated liver disease.alt

Read more:

Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients

Chronic hepatitis B treatment using entecavir (Baraclude) for 1 year is good, but 3 years is better, according to an international study published in the September 2010 issue of Hepatology. Patients who received at least 3 years of cumulative entecavir therapy showed substantial histological improvement on liver biopsies and experienced regression of liver fibrosis or cirrhosis.

Read more:

Appetite-regulating Hormone Ghrelin May Inhibit Inflammation and Liver Fibrosis

Ghrelin, an appetite-regulating hormone produced primarily in the stomach, reduced liver fibrosis, inflammation, and oxidative stress in rats and protected them from both chronic and acute liver injury, according to a study published in the March 2010 issue of Hepatology. Researchers also found that ghrelin levels were lower in chronic hepatitis patients with advanced fibrosis. If confirmed in future studies, ghrelin may have potential as an anti-fibrotic therapy.

Read more:

Sex Hormone Receptor May Explain Higher Risk of Hepatocellular Carcinoma in Men

Interaction between hepatitis B virus (HBV) and the androgen receptor in the liver promotes viral replication and triggers cell changes that lead to development of hepatocellular carcinoma, according to a study in mice described in the May 19, 2010 issue of Science Translational Medicine. Since men have more active androgen receptors than women, these findings help explain why men with hepatitis B are more prone to liver cancer, and suggest that blocking androgen receptors in the liver might be an effective treatment.

Read more:

Bone Loss and Vitamin D Deficiency Are Common among People with Liver Cirrhosis

People with liver cirrhosis -- a potential outcome of chronic hepatitis B or C -- frequently experience bone loss, or reduced bone mineral density (BMD), and often have low vitamin D levels, according to an Indian study published in the July 28, 2009 issue of World Journal of Gastroenterology.

Read more: